Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant ...

Dr Hope Rugo explores how evolving endocrine strategies and targeted therapies are enhancing outcomes in hormone ...

Progesterone Receptor Positive (PR+) breast cancer is a distinct biological subtype of hormone receptor positive breast cancer. This type of cancer grows in response to progesterone, a hormone ...

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

Endocrine therapy is a type of hormone therapy used to treat hormone receptor positive breast cancer. Endocrine therapy works by blocking the body’s natural hormones that can feed the cancer cells.

Caris Life Sciences (CAI) published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug ...

Li Y, Yang D, Yin X, et al. Clinicopathological characteristics and breast cancer–specific survival of patients with single hormone receptor–positive breast cancer.

The POSITIVE trial was supported by the ETOP IBCSG Partners Foundation (globally) and the Alliance for Clinical Trials in Oncology (in North America), in collaboration with the Breast International ...

This study demonstrates that reducing estrogen levels in estrogen-receptor-positive breast cancer changes the genetics of the tumor, and these changes may be important for deciding how best to ...

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.